| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 09/29/2005 | WO2005028516A3 Albumin-binding derivatives of therapeutic peptides |
| 09/29/2005 | WO2005011584A3 Decorin proteoglycan inhibitor of fibrinogen blood clotting |
| 09/29/2005 | WO2005003295A3 Methods and compositions for maturing dendritic cells utilizing inosine-containing compounds |
| 09/29/2005 | WO2004012662A3 Improved treatment of cancer with glutamine |
| 09/29/2005 | US20050216959 Using biobolistic electric discharge particle acceleration to transfer gold coated beads into cells; improving heterologous gene transfer and expression |
| 09/29/2005 | US20050215722 Drug delivery compositions and medical devices containing block copolymer |
| 09/29/2005 | US20050215710 water soluble polymer conjugated to a drug; polymer is eliminated from the body without unwanted accumulation, as measured by formation of kidney vacuoles; PEG block polymers linked by labile hydrolytically or proteolytically degraded groups (amides); leptin, tumor necrosis factor receptor, L1-7 peptide |
| 09/29/2005 | US20050215643 A fast-release diclofenac dosage or its alkali salt in the form of a packet of powder for dissolving or suspending in water, a bilayered tablet that has a fast and a slow release layer, or a liquid drop solution; improving the taste/reducing side effects by the addition of an alkali bicarbonate; times |
| 09/29/2005 | US20050215633 Use of neurotoxic substances for the production of a means for the treatment of joint paint and method for application of said means |
| 09/29/2005 | US20050215615 Medical compositions for intravesical treatment of bladder cancer |
| 09/29/2005 | US20050215579 consisting of lung, renal, prostate, uterine, melanoma and breast tumors; cyclodextrin inclusion compounds aid solubility |
| 09/29/2005 | US20050215538 Method of treating human skin and a skin care composition for use in such a method |
| 09/29/2005 | US20050215525 Anti-infective phosphonate analogs |
| 09/29/2005 | US20050215520 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process |
| 09/29/2005 | US20050215515 Viscoelastic composition, method of use and package |
| 09/29/2005 | US20050215500 aoaligonucleotides containing activated lymphocytes; antibody therapy; skin disorders; antiallergens |
| 09/29/2005 | US20050215485 Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
| 09/29/2005 | US20050215475 Transmucosal delivery of peptides and proteins |
| 09/29/2005 | US20050215470 peptides and/or conjugated peptides may be used as therapeutics or prophylactics for the treatment of diseases mediated by B1 activation, including inflammation and chronic pain states of inflammatory and neuropathic origin, septic shock, arthritis, osteoarthritis, angina, asthma, allergic rhinitis |
| 09/29/2005 | US20050215467 Multimeric Apo A-I agonist compounds |
| 09/29/2005 | US20050215455 Surfactants in powdered form that can be used in tablets or gelatin capsules; preparation process and compositions containing them |
| 09/29/2005 | US20050215454 providing a starting mixture comprising an alk(en)yl polyglycoside, and one or more fatty alcohols, reacting starting mixture with a compound selected from omega -halocarboxylic acids, omega -halocarboxylic acid salts, omega -halocarboxylic acid esters or mixture to perform esterification |
| 09/29/2005 | US20050214901 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| 09/29/2005 | US20050214859 Hepatocyte growth factor (HGF) receptor complex for identifying modulator for prevention and treatment of cell proliferative disorders |
| 09/29/2005 | US20050214853 Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter |
| 09/29/2005 | US20050214424 Sugar-free hard coatings prepared from liquid maltitol comprising dp4+fraction |
| 09/29/2005 | US20050214382 Zinc preservative composition and method of use |
| 09/29/2005 | US20050214379 Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers |
| 09/29/2005 | US20050214378 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s) |
| 09/29/2005 | US20050214376 Hydrogel-containing medical articles and methods of using and making the same |
| 09/29/2005 | US20050214375 Process for producing block copolymer/drug composite |
| 09/29/2005 | US20050214363 Administering an immediate release oral dosage of diclofenac or in salt form together with one or more alkali metal bicarbonates in an amount of >20% by weight; palatable and free from any unpleasant taste or side effects; short time to the maximum plasma concentration; high maximum plasma concentration |
| 09/29/2005 | US20050214360 Diclofenac sodium oral pharmaceutical |
| 09/29/2005 | US20050214357 Phospholipids bilayer and aqueous core, hydrophobic drug, vitamin E derivative, and phosphatidyl choline; sonication; homogenization; increased encapsulation efficiency |
| 09/29/2005 | US20050214356 Self assembling activation agents targeted using active drug release |
| 09/29/2005 | US20050214353 Matrix for administering ergoline compounds such as lisuride; restless leg syndrome; circadian rhythm disorders; Parkinson's disease |
| 09/29/2005 | US20050214352 Patch and process for producing the same |
| 09/29/2005 | US20050214347 For affecting basal metabolic rate and/or protein metabolism |
| 09/29/2005 | US20050214346 For reducing serum cholesterol by increasing high density lipoprotein concentration; hypercholesterolemia |
| 09/29/2005 | US20050214334 Composition for topical substance delivery |
| 09/29/2005 | US20050214331 Pharmaceutical compositions for bioactive peptide agents |
| 09/29/2005 | US20050214326 Amino acid and zinc containing botulinum toxin pharmaceutical compositions |
| 09/29/2005 | US20050214318 Immunogenic composition and method of developing a vaccine based on fusion protein |
| 09/29/2005 | US20050214317 A binding site of the cystosolic protein cyclophilin A on human immunodeficiency virus capsid protein, which may be expressed by a recombinant viral, bacterial or yeast carrier; may be treated with neuraminidase or trypsin to remove sialic acid; immune stimulant such as teichoic acid or zymosan |
| 09/29/2005 | US20050214310 Drug delivery of an antibody-enzyme conjugate of an antibody (monoclonal antibody L49) reactive with an antigen on the surface of tumor cells conjugated to an enzyme ( beta-lactamase) that converts a nitrogen mustard-type prodrug into the more cytotoxic parent drug |
| 09/29/2005 | US20050214307 Antibody conjugates for treatment of neoplastic disease |
| 09/29/2005 | US20050214304 Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
| 09/29/2005 | US20050214286 Polymer-bound antibody cancer therapeutic agent |
| 09/29/2005 | US20050214284 Soluble TCR molecules and methods of use |
| 09/29/2005 | US20050214278 Antibody-containing solution pharmaceuticals |
| 09/29/2005 | US20050214272 Antiinflammatory agents for gastrointestinal inflammation involved with inflammatory bowel disease or irritable bowel syndrome |
| 09/29/2005 | US20050214248 Non-glycosylated polyacrylamide conjugates and their use for cytoprotection |
| 09/29/2005 | US20050214247 Glycodendrimers having biological activity |
| 09/29/2005 | US20050214241 Polyunsaturated fatty acid fractions of Nigella sativa L. seeds |
| 09/29/2005 | US20050214227 Needleless syringe dosage formulations |
| 09/29/2005 | US20050214225 Flushing away allergens, microbes, mucosal by products and dust particles; syringe injecting aqueous saline solution containing sesame oil combined with peppermint and/or eucalyptus oil; promoting healing after surgery; simple, low cost |
| 09/29/2005 | DE10393402T5 Mittel und Toilettenartikel- oder pharmazeutische Zusammensetzung zum Beschleunigen der Aufnahme von basischen Aminosäuren in Zellen Means and Toilettenartikel- or pharmaceutical composition to accelerate the uptake of basic amino acids in cells |
| 09/29/2005 | DE102004011686A1 Dermales oder transdermales therapeutisches System mit Matrixbestandteil aus nachwachsendem Rohrstoff Dermal or transdermal therapeutic system with matrix component from a renewable fuel pipe |
| 09/29/2005 | DE102004011663A1 Erythropoietin-Flüssigformulierung Erythropoietin liquid formulation |
| 09/29/2005 | CA2562388A1 Emulsion-stabilized preparation |
| 09/29/2005 | CA2560959A1 Method of producing coated fine particles |
| 09/29/2005 | CA2560303A1 Native plant cell wall compositions and methods of use |
| 09/29/2005 | CA2560298A1 Preparation with elevated content |
| 09/29/2005 | CA2560259A1 Methods for increasing protein polyethylene glycol (peg) conjugation |
| 09/29/2005 | CA2560024A1 Intranasal benzodiazepine compositions |
| 09/29/2005 | CA2559721A1 Expansion of neural stem cells with lif |
| 09/29/2005 | CA2559658A1 Antibody calicheamicin conjugates |
| 09/29/2005 | CA2559579A1 Thermoplastic films and methods for making |
| 09/29/2005 | CA2559161A1 Irna agents targeting vegf |
| 09/29/2005 | CA2558737A1 Antibody calicheamicin conjugates for passive targeting |
| 09/29/2005 | CA2558730A1 Support system in the form of protein-based nanoparticles for the cell-specific enrichment of pharmaceutically active substances |
| 09/29/2005 | CA2558583A1 Polymer-based compositions and conjugates of hiv entry inhibitors |
| 09/29/2005 | CA2558254A1 Cream-gel containing ivermectin |
| 09/29/2005 | CA2557866A1 Calicheamicin conjugation by antibody deglycosylation |
| 09/29/2005 | CA2557795A1 Ophthalmic solution comprising sodium carboxymethylcellulose and hydroxypropylmethylcellulose |
| 09/29/2005 | CA2556032A1 Site-specific chemical modification of hiv gp41-derived peptides |
| 09/29/2005 | CA2522609A1 Methods and systems for treatment of neurological diseases of the central nervous system |
| 09/28/2005 | EP1580216A1 High-molecular weight derivatives of camptothecins |
| 09/28/2005 | EP1579877A1 Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury |
| 09/28/2005 | EP1579874A2 Conjugate having a cleavable linkage for use in a liposome |
| 09/28/2005 | EP1579873A1 Polymeric prodrugs |
| 09/28/2005 | EP1579857A1 Chemically stable compositions of 4-hydroxy tamoxifen |
| 09/28/2005 | EP1579856A1 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| 09/28/2005 | EP1579855A1 Novel dry powder inhalation system for transpulmonary administration |
| 09/28/2005 | EP1579854A1 Dermal or transdermal therapeutic system comprising a matrix with a renewable raw material |
| 09/28/2005 | EP1579853A2 Sustained release dosage form having latex coating and method of making the same |
| 09/28/2005 | EP1579850A2 A pharmaceutical composition containing liposomes for treating a cancer |
| 09/28/2005 | EP1579506A2 Water soluble metal and semiconductor nanoparticle complexes |
| 09/28/2005 | EP1578980A2 Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer |
| 09/28/2005 | EP1578924A2 Genomic screen for epigenetically silenced tumor suppressor genes |
| 09/28/2005 | EP1578843A1 Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof |
| 09/28/2005 | EP1578842A2 Hydrolytically stable maleimide-terminated polymers |
| 09/28/2005 | EP1578841A2 Maleamic acid polymer derivatives and their bioconjugates |
| 09/28/2005 | EP1578803A1 Mixed esters of hyaluronic acid with retinoic and butyric acids |
| 09/28/2005 | EP1578789A1 Nucleic acid comprising a sequence encoding a modified glutenin polypeptide |
| 09/28/2005 | EP1578785A1 Peptides that bind to the heparin binding domain of vegf and vegfr-2 |
| 09/28/2005 | EP1578784A2 Peptides that bind to the vegfr-2 |
| 09/28/2005 | EP1578772A2 Cytokines and cytokine receptors with reduced immunogenicity |
| 09/28/2005 | EP1578771A2 Remodeling and glycoconjugation of peptides |
| 09/28/2005 | EP1578450A1 Amplification of biotin-mediated targeting |